• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[化疗药物、结直肠癌治疗中的缓解率及耐药机制]

[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].

作者信息

Tegze Bálint, Tulassay Zsolt, Gyôrffy Balázs

机构信息

II. sz. Belgyógyászati Klinika, Semmelweis Egyetem, Budapest, Hungary.

出版信息

Magy Onkol. 2006;50(4):315-23. Epub 2007 Jan 10.

PMID:17216005
Abstract

Colorectal carcinoma is one of the most common cancers in Hungary, responsible for about 5000 deaths each year. In the first line treatment the most commonly used drugs are 5-fluorouracil, oxaliplatin and irinotecan. The most frequently used drug is 5-fluorouracil, which has no effect in 90% of the cases. In combination with leukovorin or with 5-ethyl-2'-deoxyuridin fluorouracil has an increased effect. The main mechanisms of the resistance against 5-fluorouracil are due to the overexpression of dihydropyrimidine dehydrogenase, MRP8, thymidylate synthase, and NFkB p65. Oxaliplatin forms reactive platinum complexes, which are believed to inhibit DNA synthesis by forming interstrand and intrastrand cross-linking of DNA molecules. The oxaliplatin-5-fluorouracil-leucovorin combination was the first to reach more than 20 months median survival. The main mechanisms of resistance are decreased accumulation, increased detoxification and increased DNA repair. Irinotecan inhibits the topoisomerase I enzyme, resulting in the inhibition of the repair of DNA breaks occurring during DNA synthesis. With sequential 5-fluorouracil, oxaliplatin, irinotecan combination 26 months median survival was reached. Mechanisms resulting in resistance are decreased accumulation, increased enzymatic detoxification, alterations of ABC transporters, DNA repair system, apoptotic pathways and topoisomerase I. Survival can be elongated using biological therapy (cetuximab, bevacizumab). In the near future biological therapy is expected to spread.

摘要

结直肠癌是匈牙利最常见的癌症之一,每年导致约5000人死亡。一线治疗中最常用的药物是5-氟尿嘧啶、奥沙利铂和伊立替康。最常用的药物是5-氟尿嘧啶,其在90%的病例中无效。与亚叶酸或5-乙基-2'-脱氧尿苷联合使用时,氟尿嘧啶的效果会增强。对5-氟尿嘧啶耐药的主要机制是二氢嘧啶脱氢酶、MRP8、胸苷酸合酶和NFkB p65的过表达。奥沙利铂形成活性铂配合物,据信通过形成DNA分子的链间和链内交联来抑制DNA合成。奥沙利铂-5-氟尿嘧啶-亚叶酸联合方案是首个使中位生存期超过20个月的方案。耐药的主要机制是蓄积减少、解毒增加和DNA修复增加。伊立替康抑制拓扑异构酶I,导致DNA合成过程中发生的DNA断裂修复受到抑制。采用5-氟尿嘧啶、奥沙利铂、伊立替康序贯联合方案,中位生存期达到了26个月。导致耐药的机制包括蓄积减少、酶解毒增加、ABC转运蛋白改变、DNA修复系统、凋亡途径和拓扑异构酶I改变。使用生物疗法(西妥昔单抗、贝伐单抗)可延长生存期。在不久的将来,生物疗法有望得到推广。

相似文献

1
[Chemotherapy agents, response rates and mechanisms of resistance in the therapy of the colorectal carcinoma].[化疗药物、结直肠癌治疗中的缓解率及耐药机制]
Magy Onkol. 2006;50(4):315-23. Epub 2007 Jan 10.
2
Methods of overcoming treatment resistance in colorectal cancer.克服结直肠癌治疗抵抗的方法。
Crit Rev Oncol Hematol. 2014 Feb;89(2):217-30. doi: 10.1016/j.critrevonc.2013.08.015. Epub 2013 Sep 8.
3
[Recent results of irinotecan therapy in colorectal cancer].[伊立替康治疗结直肠癌的近期结果]
Magy Onkol. 2004;48(4):281-8. Epub 2005 Jan 17.
4
Chemotherapy of metastatic colorectal cancer.转移性结直肠癌的化疗
Prescrire Int. 2010 Oct;19(109):219-24.
5
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.奥沙利铂在晚期转移性结直肠癌治疗中的作用:前景与未来方向。
Semin Oncol. 2002 Oct;29(5 Suppl 15):34-9. doi: 10.1053/sonc.2002.35531.
6
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.西妥昔单抗联合XELIRI或XELOX用于转移性结直肠癌的一线治疗。
Clin Colorectal Cancer. 2008 Mar;7(2):110-7. doi: 10.3816/CCC.2008.n.015.
7
[Systemic therapy for colorectal cancer].[结直肠癌的全身治疗]
Chirurg. 2005 Jun;76(6):570-2, 574. doi: 10.1007/s00104-005-1038-6.
8
Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.在德国环境下,针对 K-ras 野生型结直肠癌患者肝内初始不可切除转移的靶向治疗药物西妥昔单抗的成本效益分析。
Clin Ther. 2011 Apr;33(4):482-97. doi: 10.1016/j.clinthera.2011.04.010.
9
Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.转移性结直肠癌的化疗:氟尿嘧啶加亚叶酸以及伊立替康或奥沙利铂。
Prescrire Int. 2005 Dec;14(80):230-3.
10
The role of new agents in the treatment of colorectal cancer.新型药物在结直肠癌治疗中的作用。
Oncology. 2004;66(1):1-17. doi: 10.1159/000076329.

引用本文的文献

1
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.S-1 联合雷替曲塞治疗难治性转移性结直肠癌:一项 II 期临床试验。
Oncologist. 2019 May;24(5):591-e165. doi: 10.1634/theoncologist.2018-0901. Epub 2019 Jan 16.